北京儿童医院张蕊、张晴、尉莉和段彦龙团队证明芦可替尼可用于治疗儿童HAVCR2突变相关噬血细胞性淋巴组织细胞增多症

The teams of Zhang Rui,Zhang Qing,Wei Li and Duan Yanlong from Beijing Children's Hospital have demonstrated that Lucitinib can be used to treat children with HAVCR2 mutation related hemophagocytic lymphohistiocytosis

近期,国家儿童医学中心、首都医科大学附属北京儿童医院张蕊、张晴、尉莉和段彦龙教授团队在《英国血液学杂志》(BRITISH JOURNAL OF HEMATOLOGY,IF=6.5)上发表了题为“Efficacy of ruxolitinib for HAVCR2mutation-associated hemophagocytic lymphohistiocytosis and panniculitis manifestations in children”的文章,证明了芦可替尼在儿童HAVCR2突变相关噬血细胞性淋巴组织细胞增多症(HLH)和脂膜炎中可获得良好的疗效。